{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Solid+Tumors", "query": { "condition": "Advanced or Metastatic Solid Tumors" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 854, "total_pages": 86, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+or+Metastatic+Solid+Tumors&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-11T01:31:39.693Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05791448", "title": "AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cholangiocarcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Neoplasm in the Liver", "Refractory Malignant Solid Neoplasm", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "RNA Transcription Modulator AU-409", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-03-29", "completion_date": "2028-03-29", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-06-11T01:31:39.693Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05791448" }, { "nct_id": "NCT02648490", "title": "An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumour" ], "interventions": [ { "name": "HLX07", "type": "DRUG" }, { "name": "Acetaminophen", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "diphenhydramine", "type": "DRUG" }, { "name": "5-HT3 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Henlix, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2016-09", "completion_date": "2019-06-28", "has_results": false, "last_update_posted_date": "2019-07-30", "last_synced_at": "2026-06-11T01:31:39.693Z", "location_count": 1, "location_summary": "Fremont, California", "locations": [ { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02648490" }, { "nct_id": "NCT04383210", "title": "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Solid Tumor", "Pancreatic Cancer", "Lung Cancer", "Head and Neck Cancer", "Breast Cancer", "Kidney Cancer", "Colorectal Cancer", "Bladder Cancer", "Ovarian Cancer", "Sarcoma", "Gallbladder Cancer", "Bile Duct Cancer", "Esophageal Cancer", "Uterine Cancer", "Cholangiocarcinoma", "Prostate Cancer" ], "interventions": [ { "name": "Seribantumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elevation Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2020-09-29", "completion_date": "2024-02-28", "has_results": true, "last_update_posted_date": "2025-04-03", "last_synced_at": "2026-06-11T01:31:39.693Z", "location_count": 35, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04383210" }, { "nct_id": "NCT03307785", "title": "Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms", "Metastatic Cancer", "Advanced Cancer", "Solid Tumor", "Non Small Cell Lung Cancer Metastatic", "Non Small Cell Lung Cancer Stage IIIB", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Niraparib", "type": "DRUG" }, { "name": "TSR-042", "type": "DRUG" }, { "name": "Carboplatin-Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "TSR-022", "type": "DRUG" }, { "name": "Carboplatin-Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin-Nab-Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tesaro, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2017-10-12", "completion_date": "2024-12-11", "has_results": true, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-06-11T01:31:39.693Z", "location_count": 8, "location_summary": "Scottsdale, Arizona • Encinitas, California • San Marcos, California + 5 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03307785" }, { "nct_id": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Cancer", "Cutaneous Melanoma", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "AU-007", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aulos Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2022-04-04", "completion_date": "2026-06-12", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-06-11T01:31:39.693Z", "location_count": 11, "location_summary": "Miami, Florida • Grand Rapids, Michigan • Minneapolis, Minnesota + 8 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Morristown", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05267626" }, { "nct_id": "NCT06635824", "title": "Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC" ], "interventions": [ { "name": "Acasunlimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2024-11-25", "completion_date": "2028-09-30", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-06-11T01:31:39.693Z", "location_count": 36, "location_summary": "Tucson, Arizona • Los Angeles, California • Vallejo, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Ocala", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06635824" }, { "nct_id": "NCT05702424", "title": "Evaluation of IGM-7354 in Adults With Relapsed and/or Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "IGM-7354", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "IGM Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2023-01-10", "completion_date": "2024-05-31", "has_results": false, "last_update_posted_date": "2024-07-24", "last_synced_at": "2026-06-11T01:31:39.693Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Sarasota, Florida • Huntersville, North Carolina + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "Norman", "state": "Oklahoma" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05702424" }, { "nct_id": "NCT00087217", "title": "17-N-Allylamino-17-Demethoxygeldanamycin and Paclitaxel in Treating Patients With Metastatic or Unresectable Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2004-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-25", "last_synced_at": "2026-06-11T01:31:39.693Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00087217" }, { "nct_id": "NCT02540876", "title": "Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm", "Solid Neoplasm", "Unresectable Malignant Neoplasm" ], "interventions": [ { "name": "Ilorasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2015-09-08", "completion_date": "2019-02-08", "has_results": false, "last_update_posted_date": "2019-04-22", "last_synced_at": "2026-06-11T01:31:39.693Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02540876" }, { "nct_id": "NCT04586270", "title": "A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "TAS0612", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2020-10-15", "completion_date": "2024-11-14", "has_results": false, "last_update_posted_date": "2025-03-13", "last_synced_at": "2026-06-11T01:31:39.693Z", "location_count": 2, "location_summary": "Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04586270" } ] }